|Bid||0.0000 x 800|
|Ask||0.0000 x 1400|
|Day's Range||1.9200 - 2.2197|
|52 Week Range||1.4800 - 5.9100|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.40|
Subscribe to Yahoo Finance Plus to view Fair Value for GMDA
The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...
BOSTON, August 01, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, ad
BOSTON, June 13, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.